Business / Finance

RSS

Medworxx third quarter revenue increases 85.2% to $2,084,962

Medworxx Solutions Inc. announced today that it has filed with the Canadian securities authorities its Interim Consolidated Financial Statements (Unaudited), and Management's Discussion and Analysis report for the three and nine month interim periods ended September 30, 2012.

23 Nov 2012

Allon Files Preliminary Shelf Prospectus

Allon Therapeutics Inc. has filed a preliminary short form base shelf prospectus with the securities commissions in each province and territory of Canada (other than Quebec).

23 Nov 2012

Cynosure closes underwritten registered public offering of class A common stock

Cynosure, Inc., a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced the closing of its previously announced underwritten registered public offering of class A common stock.

21 Nov 2012

Reckitt Benckiser to acquire Schiff

Reckitt Benckiser Group PLC today announces it has signed a definitive merger agreement with Schiff Nutrition International, Inc. a leading provider of branded vitamins, nutrition supplements and nutrition bars in the United States and elsewhere. The Board of Directors of Schiff has approved the transaction and will recommend that its stockholders tender their shares into Reckitt Benckiser's previously announced cash tender offer of $42.00 per share, valuing Schiff at $1.4 billion.

21 Nov 2012

AspenBio Pharma closes underwritten public offering of 1,946,000 shares of common stock

AspenBio Pharma, Inc., an in vitro diagnostic company, today announced the closing of an underwritten public offering of 1,946,000 shares of common stock at an offering price of $2.10 per share.

21 Nov 2012

Concord Medical third quarter 2012 total net revenues increase 65.2% to RMB206.1 million

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China and the parent of Chang'an Hospital, today reported its unaudited consolidated financial results for the third quarter ended September 30, 2012.

21 Nov 2012

Alpha Imaging announces acquisition of Chesapeake Applications

Alpha Imaging LLC, a leading distributor of advanced medical imaging equipment based in Cleveland, Ohio, today announced they have acquired Chesapeake Applications Inc., a Pennsylvania-based company, to enhance their clinical applications training portfolio.

21 Nov 2012

Patheon to launch $30 million transferable rights offering

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it will launch a U.S. $30 million transferable rights offering.

19 Nov 2012

CCBC second quarter 2013 revenues increase 30.5% to RMB128.5 million

China Cord Blood Corporation, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the second quarter and first half of fiscal year 2013, which ended September 30, 2012.

19 Nov 2012

Thermo Fisher announces opening of new facility in Suzhou, China

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its new facility in Suzhou, China, for the manufacturing of life sciences consumables and equipment. The facility expands the company's global manufacturing footprint and establishes local production capabilities to meet increased customer demand in China and other Asia-Pacific markets.

From Thermo Fisher Scientific Inc. 16 Nov 2012

Courtagen, AGBL enter exclusive distribution agreement for clinical tests

Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders.

15 Nov 2012

EpiCept third quarter revenue increases to $0.9 million

EpiCept Corporation today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million.

14 Nov 2012

AspenBio Pharma provides clinical and business update for third quarter 2012

AspenBio Pharma, Inc., an in vitro diagnostic company, today provided a clinical and business update for the third quarter 2012. The Company reported it has started the hospital training phase of its pivotal U.S. clinical study and remains on track to initiate patient enrollment before the end of the year.

13 Nov 2012

Key areas of disease neglected by UK funding for infectious diseases

UK funding for infectious diseases research is neglecting some of the diseases that result in the highest rates of death and disability, according to an Article published Online First in The Lancet Infectious Diseases.

8 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012

Lower 3rd quarter earnings for Health Net, Humana - but optimism still reigns

Woodland Hills insurer Health Net Inc. said third-quarter net income plunged 71%, but its shares rose as the company resolved a dispute with California officials over reimbursement for government health programs. Health Net disappointed investors in August when it slashed its full-year profit outlook and reported higher-than-expected medical costs. On Monday, Chief Executive Jay Gellert ... cited a wide-ranging agreement with California healthcare officials as a major step forward.

7 Nov 2012

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Tornier third quarter 2012 sales increase to $58.0 million

Tornier N.V., a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, today reported its financial results for the third quarter ended September 30, 2012 and updated its fiscal 2012 financial outlook.

6 Nov 2012

Omega Protein third quarter revenues increase to $77.8 million

Omega Protein Corporation, a nutritional ingredient company and the nation's leading vertically integrated producer of omega-3 fish oil and specialty fish meal products, today reported financial results for the third quarter ended September 30, 2012.

6 Nov 2012